Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + TQB2450 versus chemotherapy for recurrent or metastatic non-MSI-H/non-dMMR endometrial cancer
CTR20242153Phase 3Active
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Sep 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of anlotinib, benmelstobart in endometrial cancer (EC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Sep 2024; status: active.
02
Drugs
anlotinibbenmelstobart
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on CTR20242153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242153.